Full text
PDFSelected References
These references are in PubMed. This may not be the complete list of references from this article.
- DALESSIO D. J., CHAPMAN L. F., ZILELI T., CATTELL M., EHRLICH R., FORTUIN F., GOODELL H., WOLFF H. G. Studies on headache. The responses of the bulbar conjunctival blood vessels during induced oliguria and diuresis, and their modification by UML-491. Arch Neurol. 1961 Dec;5:590–593. doi: 10.1001/archneur.1961.00450180012003. [DOI] [PubMed] [Google Scholar]
- FRIEDMAN A. P., LOSIN S. Evaluation of UML-491 in the treatment of vascular headaches. An analysis of the effects of 1-methyl-D-lysergic acid (plus) butanolamide bimaleate (methysergide). Arch Neurol. 1961 Mar;4:241–245. doi: 10.1001/archneur.1961.00450090007002. [DOI] [PubMed] [Google Scholar]
- GRAHAM J. R. Use of a new compound, UML-491 (1-methyl-D-lysergic acid butanolamide), in the prevention of various types of headache. N Engl J Med. 1960 Dec 22;263:1273–1277. doi: 10.1056/NEJM196012222632502. [DOI] [PubMed] [Google Scholar]
- HARRIS M. C. Prophylactic treatment of migraine headache and histamine cephalalgia with a serotonin antagonist (methysergide). Ann Allergy. 1961 May;19:500–504. [PubMed] [Google Scholar]
- OSTFELD A. M., CHAPMAN L. F., GOODELL H., WOLFF H. G. Studies in headache; summary of evidence concerning a noxious agent active locally during migraine headache. Psychosom Med. 1957 May-Jun;19(3):199–208. doi: 10.1097/00006842-195705000-00005. [DOI] [PubMed] [Google Scholar]
- SICUTERI F. Prophylactic and therapeutic properties of 1-methyl-lysergic acid butanolamide in migraine. Int Arch Allergy Appl Immunol. 1959;15:300–307. doi: 10.1159/000229055. [DOI] [PubMed] [Google Scholar]
- SOUTHWELL N., WILLIAMS J. D., MACKENZIE I. METHYSERGIDE IN THE PROPHYLAXIS OF MIGRAINE. Lancet. 1964 Mar 7;1(7332):523–524. doi: 10.1016/s0140-6736(64)92910-1. [DOI] [PubMed] [Google Scholar]